15513-04-9

Upstream product

• 111-16-0 heptanedioic acid 
• 59379-00-9 benzyl 7-hydroxyheptanoate 
• 10521-07-0 pimelic acid anhydride 
• 100-51-6 benzyl alcohol 

Downstream Products

• 15513-05-0 Pimelinsaeure-benzylester-(3-dimethylamino-ethylester) 
• 78582-38-4 pimelic acid chloride monobenzyl ester 
• 153824-26-1 heptanedioic acid benzyl ester 2-trimethylsilanylethyl ester 
• 880359-84-2 4-(6-benzyloxycarbonyl-hexanoylamino)-4-(2-carboxy-ethyl)-heptanedioic acid 
• 880359-83-1 4-(6-benzyloxycarbonyl-hexanoylamino)-4-(2-tert-butoxycarbonyl-ethyl)-heptanedioic acid di-tert-butyl ester 
• 880359-85-3 4-(6-benzyloxycarbonyl-hexanoylamino)-4-[2-(2,5-dioxo-pyrrolidin-1-yloxycarbonyl)-ethyl]-heptanedioic acid bis-(2,5-dioxo-pyrrolidin-1-yl) ester 
• 1421704-50-8 benzyl 8-bromo-7-oxooctanoate 
• 1421704-51-9 tert-butyl 2-amino-5-(6-(benzyloxy)-6-oxohexyl)-1H-imidazole-1-carboxylate 
• 1421704-43-9 tert-butyl 5-(6-(benzyloxy)-6-oxohexyl)-2-(bis(tert-butoxycarbonyl)amino)-1H-imidazole-1-carboxylate 
• 1421704-48-4 C₂₀H₃₀N₄O 
• 1421704-49-5 C₂₃H₃₅N₅O₂ 
• 153824-32-9 benzyl phenethyl pimelate 

Relevant academic research and scientific papers

Design, synthesis, and biological evaluation of HDAC degraders with CRBN E3 ligase ligands

Histone deacetylases (HDACs) play important roles in cell growth, cell differentiation, cell apoptosis, and many other cellular processes. The inhibition of different classes of HDACs has been shown to be closely related to the therapy of cancers and other diseases. In this study, a series of novel CRBN-recruiting HDAC PROTACs were designed and synthesized by linking hydroxamic acid and benzamide with lenalidomide, pomalidomide, and CC-220 through linkers of different lengths and types. One of these PROTACs, denoted 21a, with a new benzyl alcohol linker, exhibited comparably excellent HDAC inhibition activity on different HDAC classes, acceptable degradative activity, and even better in vitro anti-proliferative activities on the MM.1S cell line compared with SAHA. Moreover, we report for the first time the benzyl alcohol linker, which could also offer the potential to be used to develop more types of potent PROTACs for targeting more proteins of interest (POI).

Ligand-Phospholipid Conjugation: A Versatile Strategy for Developing Long-Acting Ligands That Bind to Membrane Proteins by Restricting the Subcellular Localization of the Ligand

We hypothesized that if drug localization can be restricted to a particular subcellular domain where their target proteins reside, the drugs could bind to their target proteins without being metabolized and/or excreted, which would significantly extend the half-life of the corresponding drug-target complex. Thus, we designed ligand-phospholipid conjugates in which the ligand is conjugated with a phospholipid through a polyethylene glycol linker to restrict the subcellular localization of the ligand in the vicinity of the lipid bilayer. Here, we present the design, synthesis, pharmacological activity, and binding mode analysis of ligand-phospholipid conjugates with muscarinic acetylcholine receptors as the target proteins. These results demonstrate that ligand-phospholipid conjugation can be a versatile strategy for developing long-acting ligands that bind to membrane proteins in drug discovery.

Structural Studies on 4,5-Disubstituted 2-Aminoimidazole-Based Biofilm Modulators that Suppress Bacterial Resistance to β-Lactams

A library of 4,5-disubstituted 2-aminoimidazole triazole amide (2-AITA) conjugates has been successfully assembled. Upon biological screening, this class of small molecules was discovered as enhanced biofilm regulators through non-microbicidal mechanisms against methicillin-resistant Staphylococcus aureus (MRSA) and multidrug-resistant Acinetobacter baumannii (MDRAB), with active concentrations in the low micromolar range. The library was also subjected to synergism and resensitization studies with β-lactam antibiotics against MRSA. Lead compounds were identified that suppress the antibiotic resistance of MRSA by working synergistically with oxacillin, a β-lactam antibiotic resistant to penicillinase. A further structure-activity relationship (SAR) study on the parent 2-AITA compound delivered a 2-aminoimidazole diamide (2-AIDA) conjugate with significantly increased synergistic activity with oxacillin against MRSA, decreasing the MIC value of the β-lactam antibiotic by 64-fold. Increased anti-biofilm activity did not necessarily lead to increased suppression of antibiotic resistance, which indicates that biofilm inhibition and resensitization are most likely occurring via distinct mechanisms.

Pyrrolidine derivatives

Pyrrolidine derivatives which have the formula SPC1 Wherein R and R1 each is hydrogen, --(CH2)6 COOH, --(CH2)6 COO-- lower alkyl, or --(CH2)6 COO benzyl and R2 is hydrogen, --CO--O--(CH2)5 CH3, --CO--NH--(CH2)5 CH3 --(CH2)7 CH3 or --CH=CH--CH(OH)--(CH2)4 --CH3, at least one of R and R1 is hydrogen and R1 and R2 are not both hydrogen, are new compounds which are useful as inhibitors of prostaglandin dehydrogenase and as potentiators of prostaglandin activity.